Navigation Links
Questcor Pharmaceuticals to Present at the 24th Annual ROTH Conference on March 12, 2012
Date:3/7/2012

ANAHEIM, Calif., March 7, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) announced today that executive management will present at the 24th Annual ROTH Conference to be held on March 11-14, 2012 in Laguna Niguel, CA.  Don M. Bailey, President and Chief Executive Officer, is scheduled to present an overview of the Company on Monday, March 12, 2012 at 8:30 a.m. PT.

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm.  The replay will be available for 90 days after the event.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Questcor currently generates substantially all of its net sales from: the treatment of patients with acute exacerbations of multiple sclerosis in adults, the treatment of patients with nephrotic syndrome, and the treatment of patients with infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently planning to explore the potential initiation of a commercial effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Lupus, and Dermatomyositis (Polymyositis).  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Recognized by Child Neurology Foundation for Outstanding Corporate Responsibility and Leadership
2. Questcor Pharmaceuticals Appoints Scott M. Whitcup, M.D., to Board of Directors
3. Questcor Pharmaceuticals Responds to Questions From Investor Blog
4. Questcor Pharmaceuticals Issues Statement
5. Questcor Pharmaceuticals Reports Strong Finish to 2011
6. Questcor Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference on November 30, 2011
7. Questcor Pharmaceuticals to Present at CLSAs 4th Annual AsiaUSA Forum on November 7, 2011
8. Questcor and Child Neurology Foundation Support the 3rd Annual Infantile Spasms (IS) Awareness Week
9. Questcor Reports Third Quarter Financial Results
10. Questcor to Report Third Quarter 2011 Earnings and Conduct Conference Call on October 25, 2011
11. Questcor Pharmaceuticals Announces Preliminary Operating Metrics for Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)...  West Pharmaceutical Services, Inc. (NYSE: WST ... 2017 and updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, ... Net sales at constant currency (organic) grew by 3.9%. ... compared to $0.60 in the prior-year quarter. Second-quarter 2017 ...
(Date:7/26/2017)... Aesthetics, a leading medical aesthetic clinic in Singapore ... skin conditions from the inside. The natural process of ... skin becomes more transparent due to the thinning of the epidermis. Over ... the sun contributes to aging skin, causing age spots and other ... ...
(Date:7/26/2017)... 26, 2017 The Galien Foundation announced ... USA Award Nominees. Counted among the global ... recognizes outstanding biomedical and technology product achievement that improves the ... qualify, each candidate must be U.S. Food and Drug Administration ... demonstrate tremendous potential to impact human health. Sales data are ...
Breaking Medicine Technology:
(Date:7/27/2017)... MD (PRWEB) , ... July 27, 2017 , ... ... Teams of entrepreneurs will compete to form startup companies around 117 breakthrough inventions ... Heart, Lung, and Blood Institute, and National Institute of Biomedical Imaging and Bioengineering), ...
(Date:7/27/2017)... ... July 27, 2017 , ... Cremations recently surpassed traditional burials for the ... trend is expected to continue with over 70% of Americans projected to choose cremation ... new innovations that enable families to celebrate the life of a lost loved one ...
(Date:7/26/2017)... ... 2017 , ... An inventor from Salisbury, N.C., knows the difficulties involved with ... and dignified way to keep leeches in place during therapy," she said. "That’s why ... an effective way to keep a leech in place on the skin during therapy. ...
(Date:7/26/2017)... ... July 26, 2017 , ... Written By: Ashley ... major advancement in drug therapy for patients living with relapsing and primary multiple ... novel B cell targeted therapy that has been proven to significantly reduce signs ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... Solutions as part of their continued efforts to provide innovative offerings to their ... best IT resources and build dynamic, high-performing teams to address healthcare IT’s biggest ...
Breaking Medicine News(10 mins):